The phase 3 MAGNITUDE study assessed niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC with or without alterations in homologous recombination repair associated genes.
In a randomized controlled study, adding metformin to androgen deprivation therapy for low-tumor-volume metastatic hormone-sensitive prostatecancer significantly delayed development of castration-resistant disease.
An analysis of data from the VA healthcare system revealed a gap in recommended assessments of cardiovascular risk factors among men with prostatecancer.
Retrospective study of more than 32,000 veterans sought to determine the incidence, management, and mortality of men with prostatecancer who experience depression.
Use of computed tomography and bone scans in low-risk prostatecancer cases has been in decline, but doctors continue to order these imaging modalities despite professional guidelines that do not recommend such use.